Clinical trials: Stage II Breast Carcinoma
Metastatic Breast Cancer
Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy
Hormone receptor positive breast cancer is the most common type of breast cancer, comprising 70-80% of all breast cancers. Endocrine therapy is the main type of initial treatment for patients with your type of breast cancer.
- Trial name
- NCT00759642
- Testing
- lapatinib
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- University of Kansas Medical Center
Breast Cancer, Chemotherapy
Tailored Neoadjuvant Chemotherapy for Stage II/III Breast Cancer With Tumor Size More Than 2 cm
This is a multi-center randomized phase III trial. The purpose is to evaluate and compare the pathological complete response (pCR) rates after neoadjuvant chemotherapy with tailored chemotherapeutic regimens or standard…
- Trial name
- TaiNAC (NCT00776724)
- Testing
- Taxotere , Epirubicin, E-HDFL,EP,TE,N-HDFL,NP,T-HDFL,TP
- Where
- Taiwan
- Volunteers
- 166 people
- Sponsor
- National Taiwan University Hospital
Breast Cancer
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
This study evaluated whether the addition of daily BKM120 to weekly paclitaxel was effective and safe in treating patients with HER2- locally advanced or metastatic breast cancer.
- Trial name
- BELLE-4 (NCT01572727)
- Testing
- Paclitaxel, BKM120
- Where
- 112 sites in United States, Australia and 20 more
- Volunteers
- 416 people
- Sponsor
- Novartis Pharmaceuticals
Triple Negative Breast Neoplasms
Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery
The goal of this clinical trial is to evaluate the efficacity and safety of pembrolizumab and capecitabine on the invasive disease-free survival, in participants who have triple negative breast cancer (TNBC) with residual disease…
- Trial name
- CAPPA (NCT05973864)
- Testing
- Pembrolizumab injection, Capecitabine tablets, Local radiotherapy
- Where
- 20 sites in France
- Volunteers
- 220 people
- Sponsor
- UNICANCER
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8
Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer
This early phase I trial studies the side effects of durvalumab and tremelimumab before surgery in treating patients with hormone receptor positive, HER2 negative stage II-III breast cancer.
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
- Trial name
- NCT03132467
- Testing
- Durvalumab, Tremelimumab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer
The purpose of this trial is to evaluate time to progression in women with hormone responsive advanced breast cancer treated with a combination of exemestane and fulvestrant.
- Trial name
- NCT00201864
- Testing
- Exemestane, Fulvestrant
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Breast Cancer
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
This randomized phase III trial studies cyclophosphamide and doxorubicin hydrochloride compared with paclitaxel as adjuvant therapy in treating breast cancer in women with 0-3 positive axillary lymph nodes.
- Trial name
- NCT00041119
- Testing
- AC regimen, cyclophosphamide, doxorubicin hydrochloride
- Where
- 527 sites in United States, South Africa
- Volunteers
- 3,871 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Metastatic Breast Cancer
Standard Versus Continuous Capecitabine in Advanced Breast Cancer
Capecitabine is active in metastatic breast cancer but the conventional schedule (1250 mg/m2/12 hr 2 weeks on, one week off) produces grade 2 or greater hand and foot syndrome in up to 50% of patients leading to those reductions.
- Trial name
- NCT00418028
- Testing
- Capecitabine
- Where
- Spain
- Volunteers
- 195 people
- Sponsor
- Hospital San Carlos, Madrid
Breast Cancer
Cyclophosphamide, Methotrexate, and Fluorouracil, With or Without Epirubicin Hydrochloride, in Treating Women Who Have Undergone Surgery for Breast Cancer (Group III Closed to New Patients as of 12/7/2009)
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, methotrexate, fluorouracil, and epirubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- NCT01031030
- Testing
- cyclophosphamide, epirubicin hydrochloride, fluorouracil
- Volunteers
- 800 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Triple Negative Breast Cancer
Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer
The purpose of this study is to increase survival of patients with early and locally advanced triple-negative breast cancer adding selumatinib to standard preoperative chemotherapy regimen.
- Trial name
- NCT02685657
- Testing
- Drug: Selumetinib, Doxorubicin, Cyclophosphamide
- Volunteers
- 164 people
- Sponsor
- Russian Academy of Medical Sciences
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Mobile Health to Improve Oral Chemotherapy Adherence Among Women With Breast Cancer
This clinical trial evaluates the feasibility and acceptability of a mobile health device in improving oral chemotherapy adherence in women with triple negative breast cancer that has not spread to other places in the body…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT05086731
- Testing
- Best Practice, Informational Intervention, Medical Device Usage and Evaluation
- Where
- 4 sites in United States
- Volunteers
- 33 people
- Sponsor
- Emory University
Metastatic Breast Cancer
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
The purpose of this study is to find out what effect the combination of letrozole (brand name: Femara) and dasatinib (brand name: Sprycel) has on metastatic breast cancer compared to letrozole alone
- Trial name
- NCT00696072
- Testing
- Dasatinib, Letrozole
- Where
- 27 sites in United States
- Volunteers
- 120 people
- Sponsor
- Bristol-Myers Squibb
Triple Negative Breast Cancer
NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients
This is a single-arm Phase II study to assess the efficacy of a 12-18 week neoadjuvant carboplatin, paclitaxel, and pembrolizumab (CPP) regimen in a response-adaptive manner for triple-negative breast cancer (TNBC) patients who…
- Trial name
- NeoCARD (NCT06845319)
- Testing
- Carboplatin, Paclitaxel, Pembrolizumab
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Medical University of South Carolina
TNBC - Triple-Negative Breast Cancer
LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer
To evaluate the efficacy and safety of LM108 plus toripalimab plusnab-paclitaxel or eribulin as first-line or post-line treatment in patients with metastatic triple-negative breast cancer.
- Trial name
- NCT06387628
- Testing
- LM-108, Toripalimab, Eribulin
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Fudan University
Breast Cancer
Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer
The purpose of this study is to determine the effectiveness and safety of administering Herceptin in combination with Taxol (paclitaxel) in the treatment of women with HER2-positive, early stage breast cancer prior to surgery.
- Trial name
- NCT00136539
- Testing
- Herceptin, Taxol, Adriamycin
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- Harold J. Burstein, MD, PhD
Breast Cancer
A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer
This study is being done for the following reasons: The study has two parts. The purpose of the first part (Phase I) of the study is to find out the highest dose of neratinib that can be given safely with T-DM1.
- Trial name
- NCT02236000
- Testing
- Neratinib, T-DM1
- Where
- 15 sites in United States
- Volunteers
- 49 people
- Sponsor
- NSABP Foundation Inc
Breast Cancer
Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy…
- Trial name
- NCT00002627
- Testing
- filgrastim, carboplatin, cyclophosphamide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- St. Louis University
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Tonation Breathing Technique Method to Ease Aromatase Inhibitor-induced Joint and/or Muscle Pain
This clinical trial evaluates how well tonation breathing techniques (use of a breathing and tonation [creating sounds]) works to ease pain joint and/or muscle pain in patients with stage I-III breast cancer and currently take an…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
- Trial name
- NCT05412953
- Testing
- Questionnaire Administration, Tonation Breathing Technique
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mayo Clinic
Breast Cancer, TNBC - Triple-Negative Breast Cancer
Thymalfasin Combined With Chemotherapy and Immunotherapy in TNBC Neoadjuvant Treatment
This is a prospective, open-label, single-center, phase II, randomized controlled clinical trial involving patients with triple-negative breast cancer who meet the criteria for neoadjuvant chemotherapy (T > 2 cm, N+).
- Conditions
- Breast Cancer, TNBC - Triple-Negative Breast Cancer, Immunotherapy
- Trial name
- NCT07884201
- Testing
- Thymalfasin
- Volunteers
- 572 people
- Sponsor
- Fudan University
brca1 Mutation Carrier, brca2 Mutation Carrier
Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer
RATIONALE: rucaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects and best dose of rucaparib and to see how well it works in…
- Conditions
- brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer, Ovarian Cancer
- Trial name
- NCT00664781
- Testing
- rucaparib (CO-338; formally AG-014699 or PF-01367338), protein expression analysis, western blotting
- Where
- 7 sites in United Kingdom
- Volunteers
- 78 people
- Sponsor
- Cancer Research UK
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.